ESTRO 38 Abstract book

S889 ESTRO 38

independent; minor dependents, 31%. A high comorbidity according to Charlson score: 47.6% was present. Polypharmacy (> 5 drugs), was present in 64.3%. According to Frail Frailty Questionnaire : Non fragile 64.3% and fragile 35.7%.The SPPB : serious limitation, 33.3% Criteria for malnutrition according to the MNA scale : 54.8%, normal nutritional status; risk of malnutrition 40.5% and were only malnutrition 4.8%. And according to the body mass index, normal 42.9%. The presence of cognitive impairment on the Pfeiffer scale : normal were 54.8% and severe only 5 patients, 11.9%. Classification of patients, clinical decisions and main outcomes according to CGA were: Robust : 35.7% (15/42), decided: Endocrine therapy (ET): 40%, alive with disease. All of patients, were Luminal A or B. Full-oncological treatment: 60% (Surgery+/-CT+/-RT), alive without disease. Of them, 44.44%, (4/9) were triple negatives. One patient received chemotherapy neoadjuvant and 3, surgery was initial treatment. Frail patients : 50% patients, Refused[CdS1] treatment[B2] , 23.8%. Of them, 80% were triple negatives ET: 42.85%,alive with disease. Bad prognostic patients: 28.57%, of them, refused treatment 1 patient, 16.6%, palliative treatment with ET, 66.66%. The period of follow up was 19.43 ± 26.09 months (Range 0.10-129.97). The 54.66% (23/42) were alive with disease. After the recommendation of the CGA, the proportion of patients in whom a curative treatment was decided was higher in the group of robust patients. This difference was statistically significant (p = 0.03) when comparing robust patients with both poor prognosis and fragile groups considering these together. Conclusion The CGA, the Inmunophenotype and the participation of the patient and their families were determinants of the oncological treatment decision. Exclusive endocrine therapy was the most recommended treatment, in 45.23%. Comprehensive Oncogeriatric Assessment allows oncological treatments to be personalized without reducing the quality of life. EP-1652 Stability and survival of elderly patients after palliative radiotherapy of spinal bone metastases T. Bostel 1,2,3 , R. Förster 1,4 , I. Schlampp 1 , T. Sprave 1 , S. Akbaba 1 , D. Wollschläger 5 , J. Debus 1,3 , H. Schmidberger 2 , H. Rief 1 , N.H. Nicolay 1,3,6 1 University Hospital of Heidelberg, Radiation Oncology, Heidelberg, Germany ; 2 University Medical Center Mainz, Radiation Oncology, Mainz, Germany ; 3 German Cancer Research Center DKFZ, Clinical Cooperation Unit Radiation Oncology, Heidelberg, Germany ; 4 University Hospital of Zurich, Radiation Oncology, Zurich, Switzerland ; 5 University Medical Center Mainz, Medical Biostatistics- Epidemiology and Informatics IMBEI, Mainz, Germany ; 6 University Hospital of Freiburg, Radiation Oncology, Freiburg, Germany Purpose or Objective This retrospective study aimed to evaluate the stability of spinal bone metastases (SBM) in elderly patients resulting from various solid tumors following palliative radiotherapy (RT). Material and Methods A total of 322 patients aged at least 70 years received palliative RT at two major University Hospitals. Stability assessment was based on the validated Taneichi score based on CT-imaging acquired prior to RT as well as at 3 and 6 months after RT. Furthermore, the survival time after RT (bone survival, BS) and prognostic factors for stability and survival were assessed. Results Prior to RT, 183 patients (57%) exhibited unstable SBM. Among the surviving patients, significant re-calcification and stabilization were evident in 19% (23/118) and 40% (31/78) at the follow-up examinations at 3 and 6 months after RT. In breast cancer patients, the stabilization rates

Conclusion The appropriate management of elderly cancer pts with GBM is an important concern in oncology. Our data suggest that in elderly pts in good clinical conditions and with a low FI score, extensive surgery, when feasible without adding neurological impairment, followed by adjuvant RT- TMZ, should be considered. EP-1651 Geriatric oncology for decision-making in women over 75 years with breast cancer M.D. De las Peñas-Cabrera 1 , J. Martínez Peromingo 2 , P.M. Samper Ots 1 , E. Amaya Escobar 1 , M. Hernández Miguel 1 , C. Oñoro Algar 2 , M.E. Baea Monedero 2 , C. González de Villaumbrosia 2 , J. Zapatero Ortuño 1 , S. Hoyos Simón 3 , M.R. Noguero Meseguer 4 , E. Abreu Griego 4 , M. De Matías Martínez 4 , R. Fernández Huertas 4 , A.B. Cuesta Cuesta 4 1 Hospital Rey Juan Carlos, Radiation Oncology, Mostoles - Madrid, Spain ; 2 Hospital Rey Juan Carlos, Geriatric Oncology, Mostoles - Madrid, Spain ; 3 Hospital Rey Juan Carlos, Clinical Oncologist, Mostoles - Madrid, Spain ; 4 Hospital Rey Juan Carlos, Oncology Gynecology, Mostoles - Madrid, Spain Purpose or Objective Geriatric Oncology Unit helps us to make oncological decision making, through a Comprehensive Geriatric Assessment (CGA). The objective of the present study is to describe how our patients are categorized, decisions made and the impact on oncological treatments. Material and Methods It´s a retrospective study on data prospectively recorded. From January 2017 to September 2018, 114 oncology patients, older than 75 years, were diagnosed in the University Hospital Rey Juan Carlos, Mostoles, Spain. Of them 42 patients (37.5%, 42/112) had breast cancer. All of them received a Comprehensive Geriatric Assessment. Data are shown as number and percentages and chi- squared was used for comparisons. Results Age was 83.90 ± 4.83 (range 75-94). Histology was invasive ductal carcinoma 81.0% (34/42). Inmunophenotype was: Luminal A and B in 28 cases, 66.6%. Clinical stages were: I-II in 28 cases and IV, only in 11.9%. Comprehensive Geriatric Assessment was as follows: Functional reservation , with Barthel scale, only 31% were